Interferon alpha controlled-release - Delpor

Drug Profile

Interferon alpha controlled-release - Delpor

Alternative Names: DLP-201; IFN-alpha - Delpor

Latest Information Update: 15 Aug 2016

Price : $50

At a glance

  • Originator Delpor
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Hepatitis C

Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 15 Aug 2016 Interferon alpha controlled-release - Delpor is available for licensing as of 15 Aug 2016.
  • 15 Aug 2016 Preclinical trials in Hepatitis C in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top